The Thyroid-Related Quality of Life Measure ThyPRO Has Good Responsiveness and Ability to Detect Relevant Treatment Effects
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Patient-reported outcomes have become important endpoints in comparative effectiveness research and in patient-centered health care. Valid patient-reported outcome measures detect and respond to clinically relevant changes. The purpose of this study was to evaluate responsiveness of the thyroid-related quality of life (QoL) instrument ThyPRO in patients undergoing relevant clinical treatments for benign thyroid diseases and to compare it with responsiveness of the generic SF-36 Health Survey. METHODS: A sample of 435 patients undergoing treatment completed the ThyPRO and SF-36 Health Survey (Version 2) at baseline and 6 months after treatment initiation. Responsiveness was evaluated in three thyroid patient groups: patients with hyperthyroidism (n = 66) and hypothyroidism (n = 84) rendered euthyroid after medical therapy, and patients with a clinically detectable nontoxic goiter treated with surgery or radioactive iodine and remaining euthyroid (n = 62). Changes in QoL were evaluated in terms of effect size and compared to the changes predicted by clinical experts. The responsiveness of equivalent scales from ThyPRO and SF-36 Health Survey were compared with the relative validity index. RESULTS: The ThyPRO demonstrated good responsiveness across the whole range of QoL aspects in patients with hyper- and hypothyroidism. Responsiveness to treatment of nontoxic goiter was also demonstrated for physical and mental symptoms and overall QoL, but not for impact on social life or cosmetic complaints, in contrast to clinicians' predictions. For all comparable scales except one, the ThyPRO was more responsive to treatment than the SF-36 Health Survey. CONCLUSIONS: The ThyPRO was responsive to treatment across the range of benign thyroid diseases. We suggest implementing this measurement instrument as a patient-reported outcome in clinical studies and in clinical management.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Validated versions include the full 85-item ThyPRO (64,94–97) and the 39-item ThyPRO-39 scale with the 22-item ThyPRO Composite QoL scale (98).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [95]
In the citing paper
“Additionally, the trials did not use the latest thyroid-specific outcome measures, such as ThyPRO.182”
From Hypothyroidism (2024) · cites this paper as [182]
In the citing paper
“endogenous thyrotoxicosis is well known to have the capability to result in these brain affections (110–112)”
From Levothyroxine therapy in elderly patients with hypothyroidism (2021) · cites this paper as [111]
In the citing paper
“They are not adequately responsive to changes in symptoms and QoL in patients with benign thyroid diseases (25).”
In the citing paper
“There is now a consensus that thyroid specific PROMs, ThyPRO and ThyPRO39 (a shorter version) are the best PROMs for use in RCTs (21, 22, 25).”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
(1992) · PubMed · Cited by 33,716
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401 · cited 1×
“Magnitude of change was evaluated by standardized effect sizes, calculated as mean difference divided by SD of scores at baseline (39, 40).”
MethodRevicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.012 · Cited by 2,362 · cited 5×
“Impaired Social Life 14 (20) 10 (17) 4 (17) 16 (23) 8 (13) 7 (17) 15 (20) 9 (16) 6 (18) 9 (15) 7 (13) 2 (11)”
BackgroundResultInfluentialPatient reported outcome measures could help transform healthcare
Black, N. (2013) · BMJ · doi:10.1136/bmj.f167 · Cited by 1,960
Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life
Patrick, D. L., & Deyo, R. A. (1989) · Medical Care · doi:10.1097/00005650-198903001-00018 · Cited by 1,790 · cited 2×
“Long academic education (5 y or more) 40 (9) 1 (2) 19 (23) 4 (6)”
Quality of life measurement: bibliographic study of patient assessed health outcome measures
Garratt, A., Schmidt, L., Mackintosh, A., & Fitzpatrick, R. (2002) · BMJ · doi:10.1136/bmj.324.7351.1417 · Cited by 1,192 · cited 4×
“Information not available 13 2 (3) 0 1 (2) Months from treatment initiation to completion of follow-up survey 6.”
BackgroundInfluentialReeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., Schwartz, C., Revicki, D. A., Moinpour, C. M., McLeod, L. D., et al. (2013) · Quality of Life Research · doi:10.1007/s11136-012-0344-y · Cited by 845 · cited 1×
“5) Index treatment L-T4 111 (26) 0 84 (100) 0 Antithyroid medication 86 (20) 36 (55) 0 0 Aspiration of thyroid cyst 4 (1) 0 0 0 Glucocorticoid pulse therapy 2 (0) 0 0 0 Other immunosuppressive treatment 4 (1) 2 (3) 0 0”
Cited by
Gharib, H., Papini, E., Garber, J. R., Duick, D. S., Harrell, R. M., Hegedus, L., Paschke, R., Valcavi, R., & Vitti, P. (2016) · Endocrine Practice · doi:10.4158/ep161208.gl · Cited by 1,272
Self-citation2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management
Durante, C., Hegedüs, L., Czarniecka, A., Paschke, R., Russ, G., Schmitt, F., Soares, P., Solymosi, T., & Papini, E. (2023) · European Thyroid Journal · doi:10.1530/etj-23-0067 · Cited by 425
“This should take into consideration pre-treatment symptomatology, ideally including a thyroid specific patient-reported outcome (PRO) (21), which has been cross-culturally validated (22) and for which instrument minimally important change in the quality of life has been determined (23), allowing…”
BackgroundInfluentialSelf-citationDavies, T. F., Andersen, S., Latif, R., Nagayama, Y., Barbesino, G., Brito, M., Eckstein, A. K., Stagnaro-Green, A., & Kahaly, G. J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0184-y · Cited by 398
Chaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
Selenium in thyroid disorders—essential knowledge for clinicians
Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0311-6 · Cited by 288
Self-citationJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
Self-citationWinther, K. H., Cramon, P., Watt, T., Bjorner, J. B., Ekholm, O., Feldt-Rasmussen, U., Groenvold, M., Rasmussen, Å. K., Hegedüs, L., & Bonnema, S. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156925 · Cited by 152
“A subset of the data has previously been used for a methodological evaluation of the responsiveness of the ThyPRO questionnaire [21].”
MethodSelf-citationPrimary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144
Self-citationDevelopment of a Short Version of the Thyroid-Related Patient-Reported Outcome ThyPRO
Watt, T., Bjorner, J. B., Groenvold, M., Cramon, P., Winther, K. H., Hegedüs, L., Bonnema, S. J., Rasmussen, Å. K., Ware, J. E., & Feldt-Rasmussen, U. (2015) · Thyroid · doi:10.1089/thy.2015.0209 · Cited by 132
“Responsiveness in specific diagnostic groups undergoing treatment (hyper-and hypothyroidism, respectively, treated to euthyroidism, and volume reduction of goiter) was also compared to the responsiveness previously reported for the long form (26).”
InfluentialSelf-citationTaylor, P. N., Medici, M. M., Hubalewska-Dydejczyk, A., & Boelaert, K. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01614-3 · Cited by 128
Abrahamsen, B., Jørgensen, H. L., Laulund, A. S., Nybo, M., Bauer, D. C., Brix, T. H., & Hegedüs, L. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2416 · Cited by 98
“Thyroid-related quality of life is deleteriously affected by hypothyroidism,((1)) and although therapy improves these deficits, they are not completely restored.((2)) This is not surprising because hypothyroidism, even when treated, remains associated with increased somatic((3)) as well as psychiatric morbidity.”
BackgroundSelf-citationYue, W., Wang, S., Lu, F., Li, X., Xu, H., Sun, L., Guo, L., He, Y., Wang, D., & Yin, Z. (2016) · Scientific Reports · doi:10.1038/srep37838 · Cited by 93
Mitchell, A. L., Hegedüs, L., Žarković, M., Hickey, J. L., & Perros, P. (2021) · Clinical Endocrinology · doi:10.1111/cen.14340 · Cited by 81
Self-citationWong, C. K. H., Lang, B. H. H., & Lam, C. L. K. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.03.006 · Cited by 78
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Self-citationWinther, K. H., Wichman, J. E. M., Bonnema, S. J., & Hegedűs, L. D. (2016) · Endocrine · doi:10.1007/s12020-016-1098-z · Cited by 88
Self-citationCramon, P. K., Winther, K. H., Watt, T., Bonnema, S. J., Bjørner, J. B., Ekholm, O., Grøenvold, M., Hegedűs, L. D., Feldt‐Rasmussen, U., & Rasmussen, Å. K. (2016) · Thyroid · doi:10.1089/thy.2016.0044 · Cited by 86
“A subset of the data has previously been used to evaluate responsiveness of ThyPRO (21).”
Self-citationCramon, P., Bonnema, S. J., Bjorner, J. B., Ekholm, O., Feldt-Rasmussen, U., Frendl, D. M., Groenvold, M., Hegedüs, L., Rasmussen, Å. K., & Watt, T. (2015) · Thyroid · doi:10.1089/thy.2014.0433 · Cited by 62
“The Thyroid Patient-Reported Outcome (ThyPRO) is a HRQoL instrument that can be used across all benign thyroid diseases, and it is the only thyroid-related HRQoL instrument that has been validated in patients with goiter (15–19).”
Self-citationTransplantable human thyroid organoids generated from embryonic stem cells to rescue hypothyroidism
Romitti, M., Tourneur, A., de Faria da Fonseca, B., Doumont, G., Gillotay, P., Liao, X.-H., Eski, S. E., Van Simaeys, G., Chomette, L., Lasolle, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34776-7 · Cited by 64
It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease
Girnita, L., Smith, T. J., & Janssen, J. A. M. J. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac045 · Cited by 66
“These 4 theoretical models appear congruent with the clinical responses to teprotumumab; however, only scenarios embracing the role of AABIGF-IR can fully explain the previous observations that (1) GD-IgG competes with IGF-I binding to IGF-IR and (2) IgG from patients with rheumatoid arthritis initiate IGF-IR signalin…”
BackgroundInfluentialLevothyroxine therapy in elderly patients with hypothyroidism
Effraimidis, G., Watt, T., & Feldt-Rasmussen, U. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.641560 · Cited by 60
Self-citationThyroxine and treatment of hypothyroidism: seven decades of experience
Mateo, R. C. I., & Hennessey, J. V. (2019) · Endocrine · doi:10.1007/s12020-019-02006-8 · Cited by 57
“Studies in patients with hypothyroidism rendered biochemically euthyroid with LT4 have demonstrated what appears to be residual impairment in health-related quality of life as assessed using self-administered ThyPRO and SF-36 questionnaires [59].”
MethodJasim, S., Patel, K. N., Randolph, G. W., Adams, S., Cesareo, R., Condon, E., Henrichsen, T. L., Itani, M., Papaleontiou, M., Rangel, L. G., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.02.011 · Cited by 61
Martino, G., Caputo, A., Vicario, C. M., Feldt‐Rasmussen, U., Watt, T., Quattropani, M. C. A., Benvenga, S., & Vita, R. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.667237 · Cited by 79
Self-citationSørensen, J. R., Watt, T., Cramon, P. K., Døssing, H., Hegedűs, L. D., Bonnema, S. J., & Godballe, C. (2017) · Head & Neck · doi:10.1002/hed.24886 · Cited by 55
“Weight of removed goiter Gram Median (range) 35 (7-581)”
BackgroundSelf-citationBartalena, L., & Wiersinga, W. M. (2020) · European Thyroid Journal · doi:10.1159/000510700 · Cited by 54
Selenoproteins in human body: focus on thyroid pathophysiology
Valea, A., & Georgescu, C. E. (2018) · HORMONES · doi:10.1007/s42000-018-0033-5 · Cited by 54
Johri, G., Chand, G., Mishra, A., Mayilvaganan, S., Agarwal, G., Agarwal, A., & Mishra, S. K. (2020) · World Journal of Surgery · doi:10.1007/s00268-020-05732-7 · Cited by 51
Thyroid disease‐specific quality of life questionnaires ‐ A systematic review
Uslar, V., Becker, C., Weyhe, D., & Tabriz, N. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.357 · Cited by 52
Frey, S., Figueres, L., Pattou, F. N., Bras, M. L., Caillard, C., Mathonnet, M., Hamy, A., Brunaud, L., Lifante, J., Trésallet, C., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005129 · Cited by 47
Impairment of health-related quality of life among Indian patients with hypothyroidism
Shivaprasad, C., Rakesh, B., Kolly, A., Annie, P., Amit, G., & Dwarakanath, C. S. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_702_17 · Cited by 44
How patients experience thyroid eye disease
Smith, T. J., Hegedűs, L. D., Lesser, I. M., Perros, P., Dorris, K., Kinrade, M., Troy-Ott, P., Wuerth, L., & Nori, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1283374 · Cited by 38
Self-citationIs selenium supplementation in autoimmune thyroid diseases justified?
Winther, K. H., Bonnema, S. J., & Hegedüs, L. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000356 · Cited by 36
Self-citationMirallié, É., Borel, F., Trésallet, C., Hamy, A., Mathonnet, M., Lifante, J. C., Brunaud, L., Ménégaux, F., Hardouin, J.-B., Blanchard, C. L., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0587 · Cited by 39
Treatment choice, satisfaction and quality of life in patients with Graves’ disease
Conaglen, H. M., Tamatea, J. A. U., Conaglen, J. V., & Elston, M. S. (2018) · Clinical Endocrinology · doi:10.1111/cen.13611 · Cited by 39
Midgley, J. E. M., Larisch, R., Dietrich, J. W., & Hoermann, R. (2015) · Endocrine Connections · doi:10.1530/ec-150056 · Cited by 31
Determining minimal important change for the thyroid related quality of life questionnaire ThyPRO
Nordqvist, S. F., Boesen, V. B., Rasmussen, Å. K., Feldt-Rasmussen, U., Hegedüs, L., Bonnema, S. J., Cramon, P. K., Watt, T., Groenvold, M., & Bjorner, J. B. (2021) · Endocrine Connections · doi:10.1530/ec-21-0026 · Cited by 31
Self-citationLevothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?
Michaelsson, L. F., la Cour, J. L., Medici, B. B., Watt, T., Faber, J., & Nygaard, B. (2018) · European Thyroid Journal · doi:10.1159/000490383 · Cited by 30
Self-citationRønjom, M. F., Brink, C., Bentzen, S. M., Hegedűs, L. D., Overgaard, J., Petersen, J. B. B., Primdahl, H., & Johansen, J. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1064160 · Cited by 29
Self-citationCritical Approach to Hypothyroid Patients With Persistent Symptoms
Biondi, B., Celi, F. S., & McAninch, E. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad224 · Cited by 34
Larisch, R., Midgley, J., Dietrich, J. W., & Hoermann, R. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-125064 · Cited by 30
Sørensen, J. R., Lauridsen, J. F., Døssing, H., Nguyen, N., Hegedűs, L. D., Bonnema, S. J., & Godballe, C. (2017) · European Thyroid Journal · doi:10.1159/000480348 · Cited by 28
Self-citationBrandt, F., Thvilum, M., Hegedűs, L. D., & Brix, T. H. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0306 · Cited by 28
Self-citationBjerkreim, B. A., Hammerstad, S. S., Gulseth, H. L., Berg, T. J., Omdal, L. J., Lee-Ødegård, S., & Eriksen, E. F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.816566 · Cited by 24
“ThyPRO (26), with a minimal clinical difference of 10 and standard deviation of 16, we calculated that a sample size of 43 would be sufficient to detect a significant difference with 80% power and a = 0.”
Physical performance in newly diagnosed hypothyroidism: a pilot study
Gallo, D., Piantanida, E., Veronesi, G., Lai, A., Sassi, L., Lombardi, V., Masiello, E., Premoli, P., Bianconi, E., Cusini, C., et al. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0661-7 · Cited by 24
“Over the last years, quality-oflife questionnaires have been validated for hypothyroidism [2, 3, 23].”
BackgroundInfluentialThe Impact of Post‐thyroidectomy Paresis on Quality of Life in Patients with Nodular Thyroid Disease
Sørensen, J. R., Printz, T., Iwarsson, J., Grøntved, Å. M., Døssing, H., Hegedűs, L. D., Bonnema, S. J., Godballe, C., & Mehlum, C. S. (2019) · Otolaryngology · doi:10.1177/0194599819855379 · Cited by 26
“01 MPT, s 21 (12-50) 19 (6-47) 20 (12-50) .”
Self-citationRecker, S., Voigtlaender, R., Viehmann, A., Dunschen, K., Kerp, H., Frank‐Raue, K., Leidig‐Bruckner, G., Graf, D., Lederbogen, S., Dietrich, J. W., et al. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0897-8785 · Cited by 27
“In addition to statistical significance testing, effect sizes (mean difference divided by standard deviation at baseline) were also calculated, to enhance interpretability [13].”
MethodSelf-citationNonsurgical Thermal Ablation of Thyroid Nodules: Not if, but Why, When, and How?
Hegedűs, L. D., Miyauchi, A., & Tuttle, R. M. (2020) · Thyroid · doi:10.1089/thy.2020.0659 · Cited by 22
“While we have improved our ability to evaluate the quality of life following therapeutic interventions using validated disease-specific instruments such as the ThyPRO (14), we rarely use these instruments in a routine clinical setting, and if we do, the specific thresholds that should guide us in offering or refrainin…”
MethodSelf-citationCombination Thyroid Hormone Replacement; Knowns and Unknowns
Taylor, P. N., Eligar, V., Muller, I., Scholz, A., Dayan, C., & Okosieme, O. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00706 · Cited by 21
“Potentially more robust disease-specific patient reported outcomes such as THYPRO are now available (40).”
BackgroundInfluentialHoermann, R., Midgley, J. E. M., Larisch, R., & Dietrich, J. W. (2018) · Journal of Thyroid Research · doi:10.1155/2018/3239197 · Cited by 20
Molewijk, E., Fliers, E., Dreijerink, K. M. A., van Dooren, A. A., & Heerdink, E. R. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100330 · Cited by 31
“The quality of life (QoL) was measured by the validated thyroid-specific questionnaire ThyPRO [24].”
Patients with Benign Thyroid Diseases Experience an Impaired Sex Life
Sawicka‐Gutaj, N., Ruchała, M., Feldt‐Rasmussen, U., Rasmussen, Å. K., Hegedűs, L. D., Bonnema, S. J., Grøenvold, M., Bjørner, J. B., & Watt, T. (2018) · Thyroid · doi:10.1089/thy.2017.0602 · Cited by 19
“%) comprised patients undergoing treatment for thyroid diseases at the abovementioned centers in 2008–2012, evaluated prior to and 6 months after treatment (16).”
Self-citationImplementation of thyroid-related patient-reported outcomes in routine clinical practice
Cramon, P. K., Bjørner, J. B., Grøenvold, M., Boesen, V. B., Bonnema, S. J., Hegedűs, L. D., Feldt‐Rasmussen, U., Rasmussen, Å. K., & Watt, T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1000682 · Cited by 19
Self-citationLong-term management of Graves disease: a narrative review
Kim, H. (2022) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2022.00444 · Cited by 22
“is responsive to the treatment used for benign thyroid diseases [51].”
BackgroundMehuys, E., Lapauw, B., T'Sjoen, G. G., Christiaens, T. C., Sutter, A. D., Steurbaut, S., Tongelen, I. V., & Boussery, K. (2023) · Thyroid · doi:10.1089/thy.2023.0066 · Cited by 19
“48 8 For example, online patient surveys by the American Thyroid Association 8 and the British Thyroid Foundation 7 revealed a remarkable dissatisfaction with hypothyroidism treatment.”
Boesen, V. B., Feldt‐Rasmussen, U., Bjørner, J. B., Cramon, P. K., Grøenvold, M., Nygaard, B., Rasmussen, Å. K., Vilsbøll, T., & Watt, T. (2018) · Thyroid · doi:10.1089/thy.2018.0210 · Cited by 19
Self-citationWojtas, N., Wądołowska, L., & Bandurska-Stankiewicz, E. M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16234841 · Cited by 23
“There is substantial evidence for the clinical validity and reliability of the questionnaire in patients with mild thyroid disorders [33,34].”
BackgroundWirth, U., von Ahnen, T., Hampel, J., Schardey, J., Busch, P., Schardey, H. M., & Schopf, S. K. (2021) · Surgical Endoscopy · doi:10.1007/s00464-021-08361-w · Cited by 15
The Impact of Esophageal Compression on Goiter Symptoms before and after Thyroid Surgery
Brinch, F. A., Døssing, H., Nguyen, N., Bonnema, S. J., Hegedűs, L. D., Godballe, C., & Sørensen, J. R. (2018) · European Thyroid Journal · doi:10.1159/000493542 · Cited by 16
Self-citationProblem gambling during Covid-19
Frisone, F., Alibrandi, A., & Settineri, S. (2020) · Mediterranean Journal of Clinical Psychology · doi:10.6092/2282-1619/mjcp-2457 · Cited by 32
Quality of life in thyroid cancer
Watt, T., Christoffersen, T., Brogaard, M. B., Bjørner, J. B., Bentzen, J., Hahn, C. H., Nygaard, B., & Feldt‐Rasmussen, U. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101732 · Cited by 18
Self-citationHeald, A. H., Premawardhana, L., Taylor, P., Okosieme, O., Bangi, T., Devine, H., Livingston, M., Javed, A., Moreno, G. Y. C., Watt, T., et al. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14967 · Cited by 14
Self-citationDemir, B. K., Karakılıç, E., Saygılı, E. S., Aracı, N., & Özdemir, S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.05.001 · Cited by 34
Zahan, A. E. (2018) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2018.192 · Cited by 18
Progress Toward and Challenges Remaining for Thyroid Tissue Regeneration
Romitti, M., & Costagliola, S. (2023) · Endocrinology · doi:10.1210/endocr/bqad136 · Cited by 15
Ashraf, H., Heydari, M., Shams, M., Zarshenas, M. M., Tavakoli, A., & Sayadi, M. (2022) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2022/5456855 · Cited by 13
“Hypothyroidism is a chronic disease with multiple physiological and psychological symptoms that require long-life treatment, exerting a remarkable negative effect on the patient’s quality of life (QoL) [32].”
BackgroundHoermann, R., Midgley, J. E. M., Dietrich, J. W., & Larisch, R. (2017) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018817716401 · Cited by 14
Boronat, M., González-Lleó, A. M., Rodríguez-Pérez, C., Feldt‐Rasmussen, U., López-Plasencia, Y., Rasmussen, Å. K., Alberiche-Ruano, M. P., Hegedűs, L. D., Alvarado-Martel, D., Bonnema, S. J., et al. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.06.010 · Cited by 14
Self-citationSørensen, J. R., Markoew, S., Døssing, H., Hegedűs, L. D., Bonnema, S. J., & Godballe, C. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4247-5 · Cited by 14
“Therefore, we used the goiter symptom scale of the thoroughly validated thyroid-specific patient-reported outcome measure (ThyPRO) [22–24], since single scales can be used to measure specific issues [25].”
MethodSelf-citationPustelnik, F. S., Gronbek, C., Døssing, H., Nguyen, N., Bonnema, S. J., Hegedűs, L. D., Godballe, C., & Sørensen, J. R. (2017) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-017-4777-3 · Cited by 13
“However, single scales can be used to measure specific health-related issues associated with thyroid disease [31], and for this study, only the 11-item Goiter Symptom Scale was used (Fig.”
MethodSelf-citationPredictors of Improvement in Quality of Life When Treating Hypothyroidism
Medici, B. B., la Cour, J. L., Knop, F. K., Krakauer, M., Michaelsson, L. F., Faber, J. O., Watt, T., & Nygaard, B. (2021) · Journal of Thyroid Research · doi:10.1155/2021/5577217 · Cited by 14
Self-citationUnderstanding the clinical and molecular basis of thyroid orbitopathy: a review of recent evidence
Nivean, P. D., Madhivanan, N., Kumaramanikavel, G., Berendschot, T. T. J. M., Webers, C. A. B., & Paridaens, D. A. (2023) · HORMONES · doi:10.1007/s42000-023-00498-8 · Cited by 12
“The authors have recommended its use in clinical trials as it could additionally evaluate the relationships between clinical variables and QOL [22].”
BackgroundNegro, R., & Greco, G. (2018) · International Journal of Hyperthermia · doi:10.1080/02656736.2018.1549335 · Cited by 12
Huang, H., Wang, J., & Kao, S. (2021) · Family Practice · doi:10.1093/fampra/cmab027 · Cited by 13
Boesen, V. B., Nissen, S. B., Grøenvold, M., Bjørner, J. B., Hegedűs, L. D., Bonnema, S. J., Rasmussen, Å. K., Feldt‐Rasmussen, U., & Watt, T. (2017) · Quality of Life Research · doi:10.1007/s11136-017-1762-7 · Cited by 16
Self-citationPatti, M., Christian, R., & Palokas, M. J. (2021) · JBI Evidence Synthesis · doi:10.11124/jbies-20-00043 · Cited by 14
“This review assessed the relationship between aTA and overall QoL and three secondary outcomes in individuals with euthyroid HT.”
BackgroundInfluentialEye symptoms in patients with benign thyroid diseases
Sawicka‐Gutaj, N., Ziółkowska, P., Wojciechowska, K., Shawkat, S., Czarnywojtek, A., Warchol, W. J., Sowiński, J., Szczepanek‐Parulska, E., & Ruchała, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-98232-0 · Cited by 15
Li, L., & Qiu, X. (2021) · Thyroid · doi:10.1089/thy.2021.0454 · Cited by 11
“It will be important to use validated tools, such as the ThyPRO, to assess treatment effects (50–52).”
Sørensen, J. R., Døssing, H., Watt, T., Cramon, P. K., Hegedűs, L. D., Bonnema, S. J., & Folkestad, L. (2022) · Thyroid · doi:10.1089/thy.2021.0665 · Cited by 12
“…symptom, hypothyroid symptom, eye symptom, tiredness, cognitive complaint, anxiety, depressivity, emotional susceptibility, impaired social life, impaired daily life, impaired sex life, and cosmetic complaint scales, as well as a 22-item composite score representing the overall QoL (20,23,24).”
Self-citationRecurrent goiters: risk factors, patient quality of life, and efficacy of radioiodine therapy
Sawicka‐Gutaj, N., Ziółkowska, P., Sowiński, J., Czarnywojtek, A., Milczarczyk, K., Gut, P., & Ruchała, M. (2018) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.4383 · Cited by 11
How does thyroidectomy for benign thyroid disease impact upon quality of life? A prospective study
Chew, C. R., Chin, S. L., Lam, T., Drosdowsky, A., Chan, S. T. F., & Chin‐Lenn, L. (2020) · ANZ Journal of Surgery · doi:10.1111/ans.16342 · Cited by 14
Riis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
“35,51,52 Thyroid hormone levels Since T3 has a short half-life, multiple daily dosing is required to restore a near-normal diurnal serum pro fi le of T3.”
Self-citationPAINFUL SUBACUTE THYROIDITIS TREATMENT APPROACH
Форкерт, І. О., Melekhovets, O. K., Kalynychenko, D. O., Melekhovets, Y. V., & Kovalenko, E. L. (2021) · Wiadomości Lekarskie · doi:10.36740/wlek202108125 · Cited by 10
Chaves, N., Rodriguez, M. J., Broekhuis, J. M., Chen, H. W., Bain, P. A., & James, B. C. (2022) · World Journal of Surgery · doi:10.1007/s00268-022-06452-w · Cited by 12
“This questionnaire has been validated in NTG, hyperthyroidism, hypothyroidism, and Graves’ disease orbitopathy [20].”
MethodPavlatou, M. G., Žarković, M., Hegedűs, L. D., Priestley, J., McMullan, C., & Perros, P. (2021) · Clinical Endocrinology · doi:10.1111/cen.14649 · Cited by 9
Self-citationRigó, A., Malkov, K., Szabó, A., Bognár, V. K., & Urbán, R. (2023) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-023-00606-7 · Cited by 11
“Although ThyPro shows good psychometric characteristics, content, and structural and cross-cultural validity [10, 21, 22], the need for an abbreviated version has arisen [23].”
BackgroundFunctional Thyroid Organoids—Powerful Stem Cell-Derived Models in Basic and Translational Research
Shankar, M., Boggian, A., Aparicio-Quiñonez, D., Djerbib, S., Rios-Morris, E., Costagliola, S., & Romitti, M. (2025) · Biomolecules · doi:10.3390/biom15050747 · Cited by 9
Patient needs and care: moves toward person-centered care for Graves' disease in Sweden
Lindo, A., Breikert, A., Lakwijk, P., Lundberg, C., Lunner, K., Johansson, B., & Nyström, H. F. (2023) · European Thyroid Journal · doi:10.1530/etj-23-0010 · Cited by 8
Halada, S., Baran, J. A., Isaza, A. R., Patel, T., Sisko, L., Kazahaya, K., Adzick, N. S., Katowitz, W. R., Magee, L., & Bauer, A. J. (2022) · Thyroid · doi:10.1089/thy.2022.0334 · Cited by 8
Kaniuka‐Jakubowska, S., Lewczuk, A., Majkowicz, M., Piskunowicz, M., Mizan‐Gross, K., Zapaśnik, A., Kaszubowski, M. F., Lass, P., & Sworczak, K. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00114 · Cited by 7
“J Clin Endocrinol Metab (2014) 99(10):3708–17.”
BackgroundLong-Term Outcome of Graves' Disease: A Gender Perspective
Calissendorff, J., Cramon, P. K., Hallengren, B., Khamisi, S., Lantz, M., Planck, T., Sjölin, G., Wallin, G., & Holmberg, M. (2023) · Women s Health Reports · doi:10.1089/whr.2023.0073 · Cited by 9
“25,26 Both were validated in the included populations.”
BackgroundSelf-citationGottwald-Hostalek, U., & Tayrouz, Y. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2435460 · Cited by 6
“A steady improvement in QoL (measured using ThyPRO, a thyroid specific instrument 57 ) occurred over time after the switch, with no change in body composition or heart rate 56 .”
Premawardhana, L. D., Taylor, P. N., Okosieme, O. E., Adlan, M. A., Obuobie, E. K., & Dayan, C. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1282608 · Cited by 6
“They are not adequately responsive to changes in symptoms and QoL in patients with benign thyroid diseases (25).”
BackgroundDesign of the Optimal Trial of Combination Therapy
Cappola, A. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00168 · Cited by 6
Weight Gain after Treatment of Hyperthyroidism is Associated with Impairment of Quality of Life
Kyriacou, A., Kyriacou, A., Lamnisos, D., Economides, A., Economides, P., Perros, P., & Syed, A. A. (2025) · Thyroid · doi:10.1177/10507256251404868 · Cited by 5
“We set the post-treatment SD for QoL at 20 points (based on the literature 19,26 ) and a clinically meaningful change that of one point increase in QoL (one out of 100 with a higher score indicating worse QoL, as per the ThyPRO) for a kilogram increase in weight (beta coef fi cient).”
Alfì, G., Caruso, V., Grenno, G., Gemignani, A., Antonelli, A., Fallahi, P., & Ferrari, S. M. (2026) · Clinical Endocrinology · doi:10.1111/cen.70114 · Cited by 7
“Among the disease‐specific instruments available for assessing QoL in patients with thyroid disorders, the ThyPRO (Thyroid Patient‐Reported Outcome) stands out as one of the most comprehensive and psychometrically robust tools [29].”
InfluentialAzaria, S., Cherian, A. J., Gowri, M. S., Thomas, S., Gaikwad, P., Paul, M. J., & Abraham, D. T. (2022) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-021-02391-7 · Cited by 6
“On validation, it was found to have very high agreement with the original long-form, with a good test–retest reliability [14].”
MethodMazza, A. D. (2025) · Cureus · doi:10.7759/cureus.90685 · Cited by 9
“Tools like the ThyPRO questionnaire help track issues such as fatigue, brain fog, emotional well-being, and overall quality of life [33].”
Jonklaas, J., & Bianco, A. C. (2022) · Thyroid · doi:10.1089/thy.2022.0483 · Cited by 5
“5,6 A range of validated thyroid-related PROs have been used to assess QOL 7,8 and treatment satisfaction 9,10 in patients with hypothyroidism.”
Papini, E., & Hegedűs, L. D. (2023) · Thyroid · doi:10.1089/thy.2023.0263 · Cited by 5
“…prospective head-to-head studies of the various MITs versus surgery (performed only as lobo-isthmusectomy) and include HRQoL evaluation using validated questionnaires, which can also ascertain minimal important change in HRQoL, for example, the ThyPRO, 47,48 induced by any MIT procedure.”
Self-citation
Metadata
- Authors
- Watt, T., Cramon, P., Hegedüs, L., Bjorner, J. B., Bonnema, S. J., Rasmussen, Å. K., Feldt-Rasmussen, U., & Groenvold, M.
- Affiliations
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Odense University Hospital (DK)
- Corresponding author
- Watt, Torquil
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-10
- Volume
- 99
- Issue
- 10
- Pages
- 3708-3717
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2123438362
- Cited by
- 152
- References
- 49
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 9 · 2023: 15 · 2022: 22 · 2021: 20 · 2020: 11 · 2019: 12 · 2018: 18 · 2017: 11 · 2016: 6 · 2015: 5 · 2014: 3
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- quality of life, responsiveness, patient-reported outcome measures, hyperthyroidism, hypothyroidism, nontoxic goiter, SF-36 Health Survey, thyroid dysfunction, treatment effect detection, goiter surgery, radioiodine therapy
- MeSH terms
- Adult, Aged, Female, Goiter, Health Surveys, Humans, Hyperthyroidism, Hypothyroidism, Male, Mental Health, Middle Aged, Psychometrics, Quality of Life, Treatment Outcome, Graves Ophthalmopathy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.